en · de · es
cardarine-notes.peptides8425.com › News › Background And Research Context — Worked Examples

Background And Research Context — Worked Examples

By Editorial Desk · published 2025-11-30 · last reviewed 2026-01-06 · News

Nuclear receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Last reviewed on 2026-01-06. Where a claim depends on a specific study, the study is described rather than over-claimed.

Background and Research Context

Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.

PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.

In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.

Mechanism and Safety Research

Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.

Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.

GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.

Cardarine at a glance

PropertyValueNotes
CAS Registry Number317318-70-0Unique identifier for the compound.
Chemical classPPARδ agonistSynthetic ligand for peroxisome proliferator-activated receptor delta.
AppearanceWhite to off-white solidTypical form of research-grade material.
SolubilitySoluble in DMSO and ethanolPoorly soluble in water.
Typical storage-20°CRecommended for long-term storage of stock solutions.

Regulation and Analytical Detection

Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.

Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.

Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.

Related pages on this site

Detection, Regulation, and Quality Context

Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.

Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.

Background from the literature

=== Role in cell adhesion, extravasation, migration === Acting through several integrins and probably a few yet unknown other receptors Thy-1 mediates adhesion of leukocytes and monocytes to endothelial cells and fibroblasts, melanoma cells to endothelium, and thymocytes to thymic epithelium. Thy1 expression comes on when endothelial cells are activated. It has been shown to interact with the leukocyte integrin Mac1 (CD11b/CD18) and may play a role in leukocyte homing and recruitment.

Cetrimide, or alkyltrimethylammonium bromide, is an antiseptic which is a mixture of three quaternary ammonium compounds: tetradonium bromide (TTAB or MITMAB), cetrimonium bromide (CTAB), and laurtrimonium bromide (DTAB or LTAB). It was first discovered and developed by ICI and introduced under the brand name Cetavlon. It is used as a 1-3 % solution for cleaning roadside accident wounds. ICI also introduced Savlon, which was a combination of cetrimide and chlorhexidine. ICI sold the Savlon brand OTC to Johnson & Johnson in May 1992. Cetrimide is used in various applications such as antiseptic agents, diagnostic test and analysis, topical formulations, and dental treatment.

The two substrates of this enzyme are ribitol and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are D-ribulose, reduced NADH, and a proton. This enzyme participates in pentose and glucuronate interconversions.

Based on how they splice themselves out, they can be classified into cis-splicing (which means that they splice themselves out) or trans-splicing (which means they need outside help). Most studied inteins are cis-splicing. Split inteins (see below) usually involves two halves helping each other out, so they are trans-splicing. Based on whether they contain the endonuclease domain. Ones that have an endonuclease domain is called a "maxi-intein", otherwise a "mini-intein". Based on their splicing mechanism, which can be partially inferred based on the sequence. Class 1 intein is the most-studied type and are marked by a cysteine or serine as the first residue. Class 2 intein, or "alanine intein" has alanine as the first residue and no WCT motif. Class 3 intein has alanine as the first residue and a noncontiguous "WCT" motif. It has also been proposed that inteins that start with a serine and contain a "WCT" motif should be also classed as class 3.

Sources: en.wikipedia.org

Reference notes

Serbia and Montenegro had an area of 102,350 square kilometres (39,518 sq mi), with 199 kilometres (124 mi) of coastline. The terrain of the two republics is extremely varied, with much of Serbia comprising plains and low hills (except in the more mountainous region of Kosovo and Metohija) and much of Montenegro consisting of high mountains. Serbia is entirely landlocked, with the coastline belonging to Montenegro. The climate is similarly varied. The north has a continental climate (cold winters and hot summers); the central region has a combination of a continental and Mediterranean climate; the southern region had an Adriatic climate along the coast, with inland regions experiencing hot, dry summers and autumns and relatively cold winters with heavy snowfall inland. Belgrade, with its population of 1,574,050, is the largest city in the two nations: and the only one of significant size. The country's other principal cities were Novi Sad, Niš, Kragujevac, Podgorica, Subotica, Pristina, and Prizren, each with populations of about 100,000–250,000 people.

If the person presents more than eight hours after the paracetamol overdose, then activated charcoal is not useful, and acetylcysteine is started immediately. In earlier presentations, charcoal can be given when the patient arrives and acetylcysteine is initiated while waiting for the paracetamol level results to return from the laboratory. In United States practice, intravenous (IV) and oral administration are considered to be equally effective and safe if given within 8 hours of ingestion. However, IV is the only recommended route in Australasian and British practice. Oral acetylcysteine is given as a 140 mg/kg loading dose followed by 70 mg/kg every four hours for 17 more doses, and if the patient vomits within 1 hour of dose, the dose must be repeated. Oral acetylcysteine may be poorly tolerated due to its unpleasant taste, odor, and its tendency to cause nausea and vomiting. If repeated doses of charcoal are indicated because of another ingested drug, then subsequent doses of charcoal and acetylcysteine should be staggered. Intravenous acetylcysteine is given as a continuous infusion over 20 hours for a total dose 300 mg/kg. Recommended administration involves infusion of a 150 mg/kg loading dose over 15 to 60 minutes, followed by a 50 mg/kg infusion over four hours; the last 100 mg/kg are infused over the remaining 16 hours of the protocol.

=== Comparative effectiveness === A major systematic review and network meta-analysis of medications for the treatment of insomnia was published in 2022. It found a widely varying range of effect sizes (standardized mean difference or SMD) in terms of clinical effectiveness for insomnia. The assessed medications and their effect sizes included benzodiazepines (e.g., temazepam, triazolam, many others) (SMDs 0.58 to 0.83), Z-drugs (eszopiclone, zaleplon, zolpidem, zopiclone) (SMDs 0.03 to 0.63), sedative antidepressants and antihistamines (doxepin, doxylamine, trazodone, trimipramine) (SMDs 0.30 to 0.55), the antipsychotic quetiapine (SMD 0.07), orexin receptor antagonists (daridorexant, lemborexant, seltorexant, suvorexant) (SMDs 0.23 to 0.44), and melatonin receptor agonists (melatonin, ramelteon) (SMDs 0.00 to 0.13). The certainty of evidence varied and ranged from high to very low depending on the medication. Certain medications often used as hypnotics, including the antihistamines diphenhydramine, hydroxyzine, and promethazine and the antidepressants amitriptyline and mirtazapine among others, were not included in analyses due to insufficient data.

(2017) in a Kozak-like region in the SOX9 gene that created a new translation initiation codon in an out-of-frame open reading frame. The correct initiation codon was located in a region that did not match the Kozak consensus sequence as closely as the surrounding sequence of the new, upstream initiation site did, which resulted in reduced translation efficiency of functional SOX9 protein. The patient in whom this mutation was detected had developed acampomelic campomelic dysplasia, a developmental disorder that causes skeletal, reproductive and airway issues due to insufficient SOX9 expression.

Autologous fat (fat tissue transferred from elsewhere in the body). Teflon. Bovine glutaraldehyde cross-linked collagen (collagen from cows). Carbon-coated zirconium/graphite beads ("Durasphere"). Polydimethylsiloxane elastomer (silicone) biomaterial implants ("PTQ implant"). Dextranomer in non-animal stabilised hyaluronic acid ("Solesta", "NASHA Dx"). Hydrogel cross-linked with polyacrylamide ("Bulkamid"). Porcine dermal collagen (collagen from pig skin, "Permacol"). Synthetic calcium hydroxylapatite ceramic microspheres. Polyacrylonitrile in cylinder form. aluminum potassium sulfate and tannic acid (ALTA).

Sources: en.wikipedia.org

Reference notes

By that time, BMS had already withdrawn the drug from the market in Europe, Australia, New Zealand, and Canada. In August 2020, Teva Pharmaceuticals placed nefazodone in shortage due to a shortage of a raw ingredient. On December 20, 2021, nefazodone was again made available in all strengths.

On February 6, 2017, Duterte, citing continued attacks by the NPA on the military, formally terminated peace negotiations with the CPP-NPA-NDF, designated them as a terrorist organization and ordered the arrest of all NDF negotiators. Through an executive order he issued in December 2018, Duterte established the National Task Force to End Local Communist Armed Conflict (NTF-ELCAC), an inter-agency body that involved a whole-of-nation approach—from the national to local level— in addressing the root causes of communism. The NTF-ELCAC worked in close coordination with the military and focused on developing far-flung localities infiltrated by the NPA. Duterte also granted amnesty to former communist rebels and launched reintegration programs to support them and their families. Ultimately, in March 2019, he permanently terminated peace negotiations with the CPP-NPA-NDF, facilitating localized peace talks with the rebels. Duterte left office with the number of NPA guerrilla fronts in the country reduced from 89 to 23, and about 20,579 communist rebels reportedly surrendered from 2016 to 2021. Despite its success in reducing communist insurgency in the country, Duterte's administration was marred by numerous allegations of red-tagging, notably the left-leaning Makabayan Bloc; Duterte and the military dismissed the red-tagging accusations and argued the government was merely "identifying" them as communist fronts.

== Ozempic television advertisement == In 2018, pharmaceutical company Novo Nordisk began using the song in its ads for Ozempic, an injectable drug originally intended for people with type 2 diabetes, but which became popular for its off-label use as a weight-loss drug. David Paton was asked to return to Abbey Road Studios to record a new version of the song, which from a vocal standpoint is little more than his singing the opening line, replacing the words "It's magic" with "Ozempic" and otherwise adding nonverbal singing.

The article cites the attempts to replicate Hamer's work, some supportive and some not. It concludes, "Although it is encouraging that the largest study replicated some findings from smaller studies, the case is not closed. Still larger studies are needed to provide the degree of certainty now expected in molecular genetics, and in any case, the mapping case is not closed in molecular genetics until one has identified the genes that affect a trait." Hamer and colleagues also investigated the genetic roots of anxiety and found that a promoter region polymorphism in the gene for the serotonin transporter, which is the target of antidepressant drugs such as Prozac, is associated with mood and personality. This finding has been extensively replicated and extended and its activity has been confirmed by direct brain imaging studies. In 2004, Hamer used data from ongoing behavioral genetics studies in his lab to explore the possibility of genetic influences on spirituality. In The God Gene: How Faith is Hardwired into our Genes, he proposed that a quantitative measure of self-transcendence is partially heritable and may be correlated to a specific gene, VMAT2, involved in monamine metabolism. Hamer's speculations on the possible role of genetics in religious experience were featured in a cover story in Time magazine.

Sources: en.wikipedia.org

Frequently asked questions

What is cardarine?

Cardarine is a common name for GW501516, a synthetic PPARδ agonist developed for research. It has not been approved as a medication in any country. It is classified as an unapproved drug and a prohibited substance in sport.

Is cardarine a steroid?

No. Cardarine is not an anabolic steroid; it belongs to a different chemical class that targets PPARδ. Steroids act primarily through androgen receptors, while cardarine acts through a nuclear receptor involved in metabolism.

What did animal studies find?

Some rodent studies reported increased endurance and changes in fat metabolism after cardarine exposure. Long-term studies in animals also raised concerns about cancer in certain tissues. Human trial data are limited, so these findings cannot be directly translated to people.

What is the main molecular target of cardarine?

It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.

Network